NCT05118399View on ClinicalTrials.gov

Analgesic Effect of Liposomal Bupivacaine

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

December 8, 2022

Study Completion Date

March 8, 2023

Conditions
Acute Pain
Interventions
DRUG

Bupivacaine Injection [Marcaine]

Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.

DRUG

Bupivacaine Liposome 13.3 MG/ML [Exparel]

Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT05118399 - Analgesic Effect of Liposomal Bupivacaine | Biotech Hunter | Biotech Hunter